What does the prefix BD indicate about bioequivalence?

• A. Active ingredients documented bioequivalence problems
• B. Data is insufficient to determine therapeutic equivalence
• C. Equivalent FDA classification
• D. Safe for all patients

Answer: (A)

BD flags that there are documented problems with bioequivalence for the active ingredient. In practice, this means BE between the products has not been demonstrated, so they should not be assumed interchangeable. It points to issues in how the drug is absorbed and reaches the bloodstream, rather than simply a lack of data or a blanket statement about safety. The other ideas don’t fit because BD isn’t about insufficient data, an FDA classification of equivalence, or universal safety for all patients; it specifically signals that bioequivalence has been demonstrated as problematic for that active ingredient.